Please login to the form below

Not currently logged in
Email:
Password:

Acadia Pharmaceuticals

This page shows the latest Acadia Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.

Acadia’s drive to extend use of Nuplazid hits a wall

Acadia’s drive to extend use of Nuplazid hits a wall

The drug has failed the late-stage ENHANCE trial in schizophrenia inadequately controlled by currently-approved drugs, viewed as one of Acadia’s biggest opportunities to extend the franchise. ... Shares in Acadia were down 16% remarket in the wake of

Latest news

  • Nuplazid backed by FDA panel as first-ever Parkinson's psychosis drug Nuplazid backed by FDA panel as first-ever Parkinson's psychosis drug

    Concludes Acadia Pharmaceuticals’ drug provides ‘modest but meaningful’ benefits. Acadia Pharmaceuticals is celebrating an FDA panel verdict that could set its Nuplazid drug up to be the first approved therapy for ... However, there were some

  • Striking a balance

    Xsira Pharmaceuticals, 7TM Pharma, Acadia Pharmaceuticals, Glenmark Pharmaceuticals, Esteve, Vernalis, OSI Pharmaceuticals, EPIX Pharmaceuticals, Bayer and Novasite Pharmaceuticals are all undertaking separate research projects to develop CB1

  • Thomson Scientific publishes quarterly review of phase changes in industry pipeline

    Compound. Indication. Company. trazodone. Depression. Labopharm. pimavanserin. Schizophrenia. Acadia Pharmaceuticals. salmon calcitonin. ... Compound. Indication. Company. VSF-173. Excessive sleepiness. Vanda Pharmaceuticals. APD-125. Insomnia. Arena.

More from news
Approximately 2 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Damien McDevitt moves from GSK to Acadia Pharmaceuticals Damien McDevitt moves from GSK to Acadia Pharmaceuticals

    US biopharmaceutical company Acadia Pharmaceuticals has appointed Damien McDevitt (pictured) as senior vice president of corporate development. ... Meanwhile, Acadia’s SVP, technology development and operations Jim Nash will retire in January.

  • Juniper Pharmaceuticals adds to board of directors Juniper Pharmaceuticals adds to board of directors

    Mary Ann Gray joins as audit committee chair. Boston-based Juniper Pharmaceuticals has elected Mary Ann Gray to its board of directors and appointed her as its audit committee chair. ... Dr Gray has over 20 years of biotechnology and biopharmaceutical

  • Srdjan Stankovic joins Acadia Pharmaceuticals Srdjan Stankovic joins Acadia Pharmaceuticals

    He moves to the San Diego biopharma from Alkermes. San Diego biopharmaceutical company Acadia Pharmaceuticals has appointed Srdjan (Serge) Stankovic as executive vice president, head of research and development. ... Steve Davis,  Acadia's president

More from appointments
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics